| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $77K | — | -62.6% |
| SG&A Expense | $71K | — | +31.5% |
| Operating Income | -$148K | — | +43.1% |
| Net Income | -$195K | — | — |
| EPS (Basic) | -$0.05 | — | — |
| EPS (Diluted) | -$0.05 | — | — |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $0 | -100.0% | -100.0% |
| Current Assets | $18K | -82.5% | -70.5% |
| Total Assets | $205K | -33.2% | -47.8% |
| Total Liabilities | $4.0M | +3.9% | +26.9% |
| Stockholders' Equity | -$3.7M | -5.6% | -26.9% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$73K | — | +51.3% |
| Investing Cash Flow | $2K | — | -93.8% |
| Financing Cash Flow | $39K | — | -27.8% |